: Sage Therapeutics’ stock slides 49% premarket on disappointment at FDA decision on depression treatment

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Generated by Feedzy